SEC Form 10-Q filed by Metagenomi Inc.
$MGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $10.00 | Buy | H.C. Wainwright |
| 5/2/2024 | $16.00 → $6.00 | Overweight → Neutral | JP Morgan |
| 3/5/2024 | Outperform | TD Cowen | |
| 3/5/2024 | $22.00 | Outperform | BMO Capital Markets |
| 3/5/2024 | $16.00 | Overweight | JP Morgan |
| 3/5/2024 | $23.00 | Buy | Jefferies |
| 3/5/2024 | $21.00 | Buy | Chardan Capital Markets |
| 3/5/2024 | $25.00 | Overweight | Wells Fargo |
Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for one to two DC nominations in 2025 from wave 1 Ionis collaboration programs focusing on cardiometabolic indications Novel adenine base editor (ABE) and ultra small SMART editing platform demonstrated highly efficient and precise editing and wide targetability Well capitalized with $274.6 million in cash, cash equivalents and available-for-sale marketable securities at the end of Q3 2024; cash runway anticipated to support operating plans into 2027 EMERYVILLE, Calif., Nov. 13, 2024 (GLOBE
EMERYVILLE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the abstract titled "Site-Specific Insertion of Factor VIII Gene Results in Durable Factor VIII Expression in Nonhuman Primates" has been accepted for an oral presentation at the American Society of Hematology (ASH) 66th Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA, and online. "We are advancing our lead development candidate MGX-001 toward the clinic, with the goal to provide a single, curative treatment for adu
Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly specific on-target deamination with no detectable translocations and no significant genomic composition differences ABE triplex editing had no adverse effects on cell viability, expansion, or other measures of cell health EMERYVILLE, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a poster (P0533 Poster Session
4 - Metagenomi, Inc. (0001785279) (Issuer)
4 - Metagenomi, Inc. (0001785279) (Issuer)
4 - Metagenomi, Inc. (0001785279) (Issuer)
8-K - Metagenomi, Inc. (0001785279) (Filer)
10-Q - Metagenomi, Inc. (0001785279) (Filer)
8-K - Metagenomi, Inc. (0001785279) (Filer)
SC 13G - Metagenomi, Inc. (0001785279) (Subject)
SC 13G - Metagenomi, Inc. (0001785279) (Subject)
H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00
JP Morgan downgraded Metagenomi from Overweight to Neutral and set a new price target of $6.00 from $16.00 previously
TD Cowen initiated coverage of Metagenomi with a rating of Outperform
Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced data from an ongoing preclinical
EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $10 price target.
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.78) by 52.56 percent.